Table 2 Demographic and baseline characteristics
Randomized, Placebo-Controlled Trials | Long-term Safety Trials | |||||
|---|---|---|---|---|---|---|
Atogepant | Placebo | Atogepant 60 mg once daily | Standard Care | |||
10 mg once daily | 30 mg once daily | 60 mg once daily | ||||
N | 314 | 411 | 417 | 408 | 1228 | 196 |
Age, mean (SD), years | 40.8 (12.18) | 41.6 (12.58) | 41.6 (12.14) | 40.4 (12.29) | 42.2 (12.18) | 41.1 (12.09) |
BMI, mean (SD), kg/m2 | 30.22 (7.49) | 30.65 (7.42) | 29.96 (7.54) | 30.64 (8.22) | 30.6 (7.65) | 30.6 (8.03) |
Female, n (%) | 282 (89.8) | 370 (90.0) | 355 (85.1) | 352 (86.3) | 1083 (88.2) | 172 (87.8) |
Race, n (%) | ||||||
White | 250 (79.6) | 330 (80.3) | 325 (77.9) | 331 (81.1) | 994 (80.9) | 145 (74.0) |
Black/African American | 54 (17.2) | 67 (16.3) | 72 (17.3) | 69 (16.9) | 186 (15.1) | 38 (19.4) |
Asian | 3 (1.0) | 3 (0.7) | 10 (2.4) | 3 (0.7) | 21 (1.7) | 5 (2.6) |
American Indian/Alaska Native | 1 (0.3) | 2 (0.5) | 3 (0.7) | 3 (0.7) | 6 (0.5) | 0 (0) |
Native Hawaiian/Pacific Islander | 0 (0) | 2 (0.5) | 0 (0) | 0 (0) | 2 (0.2) | 2 (1.0) |
Multiple races | 6 (1.9) | 7 (1.7) | 6 (1.4) | 2 (0.5) | 18 (1.5) | 5 (2.6) |
Missing | 0 (0) | 0 (0) | 1 (0.2) | 0 (0) | 1 (0.1) | 1 (0.5) |